Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Companies

    Novartis set to bring more drugs to nation

    By ZHOU WENTING in Shanghai | CHINA DAILY | Updated: 2023-07-13 08:11
    Share
    Share - WeChat
    Visitors gather at Novartis' booth during a trade expo in Shanghai. CHINA DAILY

    Since 2022, Switzerland-based Novartis has seen 100 percent of its drug development in China achieve simultaneous development with markets worldwide, significantly narrowing the time gap between launches of new drugs in China and globally, said a senior executive of the pharmaceutical company.

    It was a major breakthrough and the company was quite agile in this respect in the industry, said Shreeram Aradhye, president of global drug development and chief medical officer for Novartis.

    "In the future, as we're in simultaneous development mode already, more and more drugs will be introduced into China for the first time," said Aradhye during a media interview in Shanghai last week.

    "It often used to be three or five years behind for a new drug to enter China after its launch in the global market — depending on the Chinese patient data that we were waiting for. We won't have such gaps anymore," he said.

    Aradhye cited the example of Pluvicto, an innovative radioligand therapeutic (RLT) for prostate cancer. RLT works by combining a targeting molecule — the ligand — that binds to a specific receptor expressed by a target cell, including cancer cells, with a radioisotope. The radiation can damage and potentially destroy the targeted cells.

    He said the company is running trials with experts in China as a way to ensure that they have the readouts that will be necessary for future approval in the country.

    "I visited Fudan University Shanghai Cancer Center during this China trip. It was amazing to see the energy that the professors there had for the work that they are doing, and we are partnering with them," he said.

    China is one of the priority geographies globally for Novartis, he said, and the company is dedicated to ensuring that it brings high-value medicines to patients to satisfy unmet medical needs.

    He added that the company is fairly rigorous in being very aware of what therapies are available and what its peer companies are working on, and then identifies rigorously the profile of a new drug that is required for it to be competitive and bring real value to patients and the healthcare system.

    He mentioned Inclisiran, an innovative therapy used to lower cholesterol, as an example. There are many mature treatments like statins in this field. But the real challenge and the unmet need in the community is some bodily intolerance for statins and medication adherence.

    Some patients, even if they have had a heart attack, are not able to take such medicines following doctor's orders to control cholesterol levels.

    Inclisiran allows patients to control cholesterol with injections twice a year with long-lasting effects, and it is a real added value for patients, said Aradhye.

    He said that the capability of the company to take on innovation challenges comes from its focused investments so that in the projects it chooses to go forward with, it is able to invest all needed efforts.

    "Focus is one of the key strengths for us as a company in the last year. We have made significant progress in transforming Novartis into a focused pharmaceutical company working in five core therapeutic areas — cardiovascular, immunology, neuroscience, solid tumors and hematology — to bring high-value innovation to patients," said Aradhye.

    Some of the therapeutic areas are also in line to help the country reduce burdens from an aging population and chronic diseases, said Rose Gao, who leads the company's drug development in China.

    "And hopefully someday when we look back, we have no regrets about how we contributed to society," she said.

    According to US industrial media Fierce Biotech, last year, the top 10 global pharmaceutical companies in terms of major business revenue cut a total of more than 50 drug development pipelines while global biopharmaceutical investment began to slow in 2022 after experiencing two years of fairly high levels during the COVID-19 pandemic.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    国产av无码专区亚洲av桃花庵| 成人午夜精品无码区久久| 久久AV高潮AV无码AV| 2021无码最新国产在线观看 | 精品无码国产一区二区三区51安| 色欲狠狠躁天天躁无码中文字幕| 人妻少妇乱子伦无码视频专区| 最近新中文字幕大全高清| 特级小箩利无码毛片| 亚洲AV无码久久精品狠狠爱浪潮 | 日韩精品无码一区二区中文字幕| 人妻精品久久无码专区精东影业| 高清无码午夜福利在线观看| 亚洲中文字幕无码爆乳AV| 国产精品无码成人午夜电影| 亚洲欧洲日产国码无码久久99| 欧美中文在线视频| 亚洲无av在线中文字幕| 无码日韩精品一区二区人妻| 精品人妻大屁股白浆无码| 亚洲综合无码精品一区二区三区 | 久久精品人妻中文系列| 国产精品无码久久久久| 免费A级毛片无码A∨| 亚洲色中文字幕无码AV| 特级做A爰片毛片免费看无码| 久久ZYZ资源站无码中文动漫| 伊人久久大香线蕉无码麻豆| 国产精品无码免费播放| 国产av无码专区亚洲国产精品| 精品无码国产一区二区三区51安| 少妇精品无码一区二区三区| 亚洲国产精品无码专区在线观看 | 人妻无码人妻有码中文字幕| 中文字幕国产在线| 最近2022中文字幕免费视频| √天堂中文官网在线| 久久婷婷综合中文字幕| 亚洲中文字幕无码一区| 中文字幕乱码中文乱码51精品| 久别的草原在线影院电影观看中文|